Detailansicht

Wissensnetz

Person

Jens Hillengaß (1974-)

Arzt

Name	Jens Hillengaß
Zeit	1974- (Lebensdaten)
Ort	Buffalo, NY (Wirkungsort) Deutschland USA
Akademischer Grad bzw. Titel	Dr. med. (Universität Heidelberg) (2003)
Beruf	Arzt (charakteristischer Beruf) Hochschullehrer
Variante	Jens Hillengass J. Hillengass
Beziehung	Medizinische Klinik und Poliklinik (Heidelberg, 5) (2002-2018) Radiologie (Thema) Bilderzeugung (Thema) Onkologie (Thema) Stammzelle (Thema)
Weitere Angaben	tätig am Roswell Park Comprehensive Cancer Center ind Buffylo, NY bis 2018: Oberarzt, Leiter der autologen Transplantations-Ambulanz, Stellvertretender Leiter der Sektion Multiples Myelom, Leitung der Arbeitsgruppe "Hämatoonkologische Bildgebung", Innere Medizin V: Hämatologie, Onkologie und Rheumatologie, Medizinische Klinik, Universitätsklinikum Heidelberg
Datensatztyp	Person
GND-Nummer	124918549
Datensatz-ID	124918549
Beteiligt an alle anzeigen Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma Genome-wide association study identifies multiple susceptibility loci for multiple myeloma Korrelation von Krankheitsaktivitätsparametern und Resilienz bei Patienten mit monoklonalen Plasmazellerkrankungen mit Messparametern der Lebensqualität und psychischer Befindlichkeit Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma Changes in bone marrow fat upon dietary-induced weight loss Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma Lack of spleen signal on diffusion weighted MRI is associated with high tumor burden and poor prognosis in multiple myeloma: a link to extramedullary hematopoiesis? Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology Automatic bone segmentation in whole-body CT images Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma Multiples Myelom und seine Vorstufen : Lebensqualität und „distress“ Virtual reality in advanced medical immersive imaging: a workflow for introducing virtual reality as a supporting tool in medical imaging Fokale Läsionen in der Ganzkörper-MRT beim multiplen Myelom : Quantifizierung der Tumorlast und Korrelation mit krankheitstypischen Parametern und Prognose Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE : a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitis Dynamische MRT des Knochenmarks zum Monitoring des Multiplen Myeloms unter Thalidomid-Monotherapie oder Kombination mit CED-Chemotherapie Charakterisierung der Angiogenese beim multiplen Myelom : angiogene Zytokine und Kontrast-verstärkte dynamische Magnetresonanztomographie

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Jens Hillengaß (1974-)

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma

Korrelation von Krankheitsaktivitätsparametern und Resilienz bei Patienten mit monoklonalen Plasmazellerkrankungen mit Messparametern der Lebensqualität und psychischer Befindlichkeit

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Changes in bone marrow fat upon dietary-induced weight loss

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma

Lack of spleen signal on diffusion weighted MRI is associated with high tumor burden and poor prognosis in multiple myeloma: a link to extramedullary hematopoiesis?

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology

Automatic bone segmentation in whole-body CT images

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

Multiples Myelom und seine Vorstufen : Lebensqualität und „distress“

Virtual reality in advanced medical immersive imaging: a workflow for introducing virtual reality as a supporting tool in medical imaging

Fokale Läsionen in der Ganzkörper-MRT beim multiplen Myelom : Quantifizierung der Tumorlast und Korrelation mit krankheitstypischen Parametern und Prognose

Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma

High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting

Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation

Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology

Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study

Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitis

Dynamische MRT des Knochenmarks zum Monitoring des Multiplen Myeloms unter Thalidomid-Monotherapie oder Kombination mit CED-Chemotherapie

Charakterisierung der Angiogenese beim multiplen Myelom : angiogene Zytokine und Kontrast-verstärkte dynamische Magnetresonanztomographie